Thrombus-specific/responsive biomimetic nanomedicine for spatiotemporal thrombolysis and alleviation of myocardial ischemia/reperfusion injury
Abstract Acute myocardial infarction (AMI) is usually caused by coronary thrombosis. However, the short half-life, lack of targetability and inevitable ischemia/reperfusion injury secondary to revascularization, which characterizes tissue plasminogen activator (tPA) limit its thrombolytic efficacy for AMI. To address the targeted and site-specific delivery of tPA, the current study reports the construction of a thrombus-targeting and responsive biomimetic nanoparticle (PTPN) for spatiotemporal treatment of AMI. PTPN was constituted by the thrombus microenvironment- responsive phenylboronic acid (PBA) nanocarrier, antioxidant molecular protocatechualdehyde (PC) and tPA with thrombolytic effect, which were enclosed by the platelet membrane. The thrombus-targeting capability of the platelet membrane enabled the adhesion of PTPN to damaged endothelial cells. The nanoparticle disintegrated under slightly acid condition and re-opened the infarct-related artery during the period of ischemia. Sequentially, ROS induced by blood reperfusion was eliminated by PC released from particle disintegration, and the cardiomyocyte mitochondrial function was protected from reperfusion injury. Therefore, this thrombus-specific/responsive biomimetic nanomedicine provides a spatiotemporal paradigm for AMI treatment with promising clinical translation prospects..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Journal of nanobiotechnology - 20(2022), 1 vom: 13. Dez. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Guo, Xiaoyu [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
© The Author(s) 2022 |
---|
doi: |
10.1186/s12951-022-01686-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2133072659 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | OLC2133072659 | ||
003 | DE-627 | ||
005 | 20240322151318.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230506s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12951-022-01686-1 |2 doi | |
035 | |a (DE-627)OLC2133072659 | ||
035 | |a (DE-He213)s12951-022-01686-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |a 610 |q VZ |
084 | |a 58.30 |2 bkl | ||
084 | |a 50.94 |2 bkl | ||
100 | 1 | |a Guo, Xiaoyu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Thrombus-specific/responsive biomimetic nanomedicine for spatiotemporal thrombolysis and alleviation of myocardial ischemia/reperfusion injury |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2022 | ||
520 | |a Abstract Acute myocardial infarction (AMI) is usually caused by coronary thrombosis. However, the short half-life, lack of targetability and inevitable ischemia/reperfusion injury secondary to revascularization, which characterizes tissue plasminogen activator (tPA) limit its thrombolytic efficacy for AMI. To address the targeted and site-specific delivery of tPA, the current study reports the construction of a thrombus-targeting and responsive biomimetic nanoparticle (PTPN) for spatiotemporal treatment of AMI. PTPN was constituted by the thrombus microenvironment- responsive phenylboronic acid (PBA) nanocarrier, antioxidant molecular protocatechualdehyde (PC) and tPA with thrombolytic effect, which were enclosed by the platelet membrane. The thrombus-targeting capability of the platelet membrane enabled the adhesion of PTPN to damaged endothelial cells. The nanoparticle disintegrated under slightly acid condition and re-opened the infarct-related artery during the period of ischemia. Sequentially, ROS induced by blood reperfusion was eliminated by PC released from particle disintegration, and the cardiomyocyte mitochondrial function was protected from reperfusion injury. Therefore, this thrombus-specific/responsive biomimetic nanomedicine provides a spatiotemporal paradigm for AMI treatment with promising clinical translation prospects. | ||
650 | 4 | |a Myocardial infarction | |
650 | 4 | |a Ischemia/reperfusion injury | |
650 | 4 | |a Mitochondrial protection | |
650 | 4 | |a pH responsive nanomedicine | |
650 | 4 | |a Platelet biomimetics | |
700 | 1 | |a Hong, Ting |4 aut | |
700 | 1 | |a Zang, Jie |4 aut | |
700 | 1 | |a Shao, Rongjiao |4 aut | |
700 | 1 | |a Hou, Xumin |4 aut | |
700 | 1 | |a Wang, Kai |4 aut | |
700 | 1 | |a Liu, Weizhuo |4 aut | |
700 | 1 | |a Su, Fan |4 aut | |
700 | 1 | |a He, Bin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of nanobiotechnology |d BioMed Central, 2003 |g 20(2022), 1 vom: 13. Dez. |h Online-Ressource |w (DE-627)362770328 |w (DE-600)2100022-0 |w (DE-576)10701548X |x 1477-3155 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2022 |g number:1 |g day:13 |g month:12 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12951-022-01686-1 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 58.30 |j Biotechnologie |j Biotechnologie |q VZ |
936 | b | k | |a 50.94 |j Mikrosystemtechnik |j Nanotechnologie |j Mikrosystemtechnik |j Nanotechnologie |q VZ |
951 | |a AR | ||
952 | |d 20 |j 2022 |e 1 |b 13 |c 12 |